[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Good Samaritan Hospital Medical Center, New York\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100580801","feasibility-trial-of-darwin-oncotreat-and-oncotarget-precision-medicine-testing-100580801",false,"NCT06842030","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients With Limited Metastatic Disease That Failed First-Line Systemic Therapy","Inclusion Criteria:\n\n* Patients age ≥18 years with metastatic solid tumor who are candidates for comprehensive involved site radiotherapy to all areas of disease seen on whole body imaging.\n* Patients with brain metastases are eligible provided they qualify as oligometastases (up to 10 lesions based on the SABR-COMET-10 trial) and are treatable with radiotherapy to all areas of visible disease.\n* Patients with adequate bone marrow (absolute neutrophil ≥1000, hemoglobin ≥ 9 g\u002Fdl, platelets ≥100,000), kidney (creatinine ≤1.5 times upper limit of normal) and liver (bilirubin ≤1.5 times upper limit of normal).\n* Patients being treated by radiation oncology at Good Samaritan University Hospital.\n\nExclusion Criteria:\n\n* Patients with an estimated median survival of less than 6 months using the published and validated NEAT methodology.\n* Patients who are pregnant and\u002For breast feeding or those with severe uncontrolled cardiac, pulmonary, infectious or organic brain disease.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology. Eligible oligometastatic patients that are receiving radiation therapy (n=20) will undergo mandatory tumor biopsy prior to precision medicine testing. Formalin fixed paraffin embedded tissue with \\>50% tumor will be sent to the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center for Darwin OncoTarget and OncoTreat testing. This will be supplementing routine clinical care with the goal of improving outcomes. The treating oncologist will decide to administer standard of care systemic therapy or proceed with treatment recommended by precision medicine testing. Feasibility outcomes include the ability to have the OncoTarget and OncoTreat test performed based on tumor type and pathology, ability to procure agents, change in medication use, and identification of unknown barriers. This study is assessing the use of precision medicine in a population has documented poor outcomes with implications aimed at improving these outcomes.",[26,27,28],"Personalized Medicine","Oligometastatic Disease","Feasibility","NOT_YET_RECRUITING","2025-02-18",{"date":32,"type":33},"2025-02-24","ACTUAL",{"date":35,"type":20},"2025-03-10",{"date":37,"type":20},"2027-04-10",{"name":39,"class":40},"Good Samaritan Hospital Medical Center, New York","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100512072","clinical-nurse-specialist-led-early-palliative-survivorship-care-for-patients-with-advanced-cancer-100512072","NCT05947695","Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer","A Randomized Controlled Trial of Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer","Inclusion Criteria:\n\n* adult patients (21 yrs and over)\n* metastatic solid tumor malignancy with very favorable and favorable prognostic curves\n* under the care of GSUH oncology and radiation oncology clinicians\n\nExclusion Criteria:\n\n* patients with metastatic solid tumor malignancy who are \\\u003C 21 yrs of age\n* adult patients with metastatic solid tumor malignancy who are in standard risk and unfavorable prognostic curves\n* patients not under the care of GSUH oncology and radiation oncology clinicians","21 Years",{"count":51,"type":20},100,[23],"The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care within two previously identified and validated patient groups having metastatic solid tumor malignancy on patient-reported symptom burden, patient-reported overall quality of life (QOL), distress, and overall survival. The primary hypothesis is that the effect of an oncology clinical nurse specialist- led early intervention multidisciplinary palliative and survivorship care model will be significantly higher, as compared to the standard of care approach to palliative and survivorship care, on the primary endpoint of patient-reported symptom burden for patients with metastatic solid tumor malignancy within favorable and very favorable risk groups. Symptom burden includes pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, shortness of breath, and wellbeing.",[55,56],"Solid Tumor, Adult","Metastasis","RECRUITING","2023-09-11",{"date":60,"type":33},"2023-09-13",{"date":62,"type":33},"2023-03-02",{"date":64,"type":20},"2029-03",{"name":39,"class":40},""]